Being long for some time, but also trying to objective it seems that we've some problem- there is not strong enough evidence that science behind CCXI platform works strong enough. So we desperately need some positive results and/or good explanation from the management what course of action they're going to take. Thee most worrisome is inconsistency with 5 & 10 mg doses after 6 weeks. The only (so far) silver lining is that some group of patients got 33% reduction which by it self(with right spin on it) allows for design of p3 trial and possibility of aproval (even with smaller potential market size). But, PR at this point is obviously lacking and I can understand point of shorting it (even though these shorts some time have no clue about fundamentals and shorting just on the basis of chart).
Its all from one poster, without a brain. Imagine, hundreds of great shorts in the market, and he decides to short a fantastic little spec, with low float, an impressive pipeline, with exceptional catalysts in the near term. I believe the smart money is loading up on CCXI here-- for big upside gains. Just hold those shares, and add on the dips.